A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasisLin Cai, Jianzhong Zhang, Jinyan Wang et al.|British Journal of Dermatology|2024Cited by 21
Ginsenoside Rg3 Ameliorates Psoriasis‐Like Dermatitis through Inhibition of NF‐κB/NLRP3 Inflammasome Signaling and Regulating Th17/Treg BalanceLiyun Gao, Congjun Jiang|Immunity Inflammation and Disease|2026Cited by 0